MyBiotics develops live biotherapeutic products using proprietary culturing technologies and an artificial donor biological bank to enhance bacterial viability and colonization. The company addresses the clinical limitations of microbiome-based therapies for conditions such as acute Clostridium difficile infection and dysbiosis, aiming to improve patient outcomes in therapeutic and food applications.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current microbiome-based therapies face limitations in bacterial viability and colonization, hindering their effectiveness in treating conditions like acute Clostridium difficile infection (CDI) and dysbiosis. Traditional probiotics often fail to deliver a sufficient quantity of live, functional bacteria to the gut, resulting in limited clinical impact.
Solution
MyBiotics develops live biotherapeutic products (LBPs) using proprietary culturing, formulation, and delivery technologies to enhance bacterial survival and engraftment. The company's approach involves single-strain and multi-strain fermentation, advanced formulation techniques, and an artificial donor biological bank to create tailored microbial consortia. These LBPs aim to restore microbial balance, improve patient outcomes, and overcome the limitations of existing microbiome-based interventions in therapeutic and food applications. MyBiotics is also developing products for oncology, gastrointestinal, and women's health indications.
Target Audience
The primary target audience includes patients suffering from acute Clostridium difficile infection, dysbiosis, and other microbiome-related disorders, as well as pharmaceutical companies seeking innovative microbiome-based therapeutics.
Features
- MyCrobe™ and SuperDonor™ technologies for improved bacterial colonization and clinical effect
- Artificial donor biological bank for sourcing diverse microbial strains
- Single-strain and multi-strain fermentation capabilities
- Advanced formulation techniques for enhanced bacterial viability
- Computational discovery and optimization platform for product development
- MBX-SD-201 and MBX-SD-202 for treating acute CDI
- MBX-MC-101 for treating acute dysbiosis